Ionis Pharmaceuticals (IONS) Income towards Parent Company (2009 - 2026)

Ionis Pharmaceuticals' Income towards Parent Company history runs 18 years deep, the most recent figure standing at -$114.6 million for Q2 2026.

• In Q2 2026, Income towards Parent Company fell 192.79% year-over-year to -$114.6 million; the TTM figure through Jun 2026 stood at -$485.3 million (down 171.95% YoY), while the FY2025 annual figure was -$301.5 million, up 17.2% from the prior year.
• Income towards Parent Company for Q2 2026 stood at -$114.6 million, down from -$92.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was $123.6 million in Q2 2025, with the low at -$149.5 million in Q4 2025.
• The 5-year median for Income towards Parent Company is -$98.9 million (2022), against an average of -$74.5 million.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company soared 612.46% in 2023, then plunged 925.95% in 2025.
• Ionis Pharmaceuticals' Income towards Parent Company stood at $13.0 million in 2022, then jumped by 612.46% to $92.4 million in 2023, then sank by 115.76% to -$14.6 million in 2024, then slumped by 925.95% to -$149.5 million in 2025, then gained by 23.3% to -$114.6 million in 2026.
• Business Quant data shows IONS's Income towards Parent Company at -$114.6 million in Q2 2026, -$92.5 million in Q1 2026, and -$149.5 million in Q4 2025.